Brokerages Set Globus Medical, Inc. (NYSE:GMED) Target Price at $106.36

Shares of Globus Medical, Inc. (NYSE:GMED) have received an average rating of “Moderate Buy” from the fifteen research firms that are currently covering the stock, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $106.3636.

Several research analysts have recently commented on the company. Needham & Company LLC boosted their target price on Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a report on Wednesday, April 15th. Truist Financial set a $115.00 target price on Globus Medical in a report on Wednesday, February 25th. Barclays boosted their target price on Globus Medical from $118.00 to $123.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Finally, Royal Bank Of Canada boosted their target price on Globus Medical from $115.00 to $120.00 and gave the stock an “outperform” rating in a report on Friday, May 8th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Glenmede Trust Co. NA boosted its holdings in shares of Globus Medical by 22.8% in the 1st quarter. Glenmede Trust Co. NA now owns 225,446 shares of the medical device company’s stock worth $19,424,000 after acquiring an additional 41,801 shares in the last quarter. Summitry LLC boosted its holdings in shares of Globus Medical by 2.6% in the 1st quarter. Summitry LLC now owns 8,205 shares of the medical device company’s stock worth $707,000 after acquiring an additional 211 shares in the last quarter. Edgestream Partners L.P. acquired a new position in shares of Globus Medical in the 1st quarter worth approximately $1,895,000. Janus Henderson Group PLC boosted its holdings in shares of Globus Medical by 4.5% in the 1st quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock worth $656,831,000 after acquiring an additional 328,217 shares in the last quarter. Finally, Arkadios Wealth Advisors boosted its holdings in shares of Globus Medical by 10.6% in the 1st quarter. Arkadios Wealth Advisors now owns 3,255 shares of the medical device company’s stock worth $280,000 after acquiring an additional 312 shares in the last quarter. 95.16% of the stock is owned by institutional investors and hedge funds.

Globus Medical Trading Down 0.5%

GMED stock opened at $82.00 on Wednesday. Globus Medical has a 1-year low of $51.79 and a 1-year high of $101.40. The firm has a market cap of $11.13 billion, a P/E ratio of 19.07, a P/E/G ratio of 1.70 and a beta of 1.00. The business’s 50 day moving average is $87.01 and its 200-day moving average is $88.41.

Globus Medical (NYSE:GMED) last released its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.20. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The company had revenue of $759.85 million for the quarter, compared to analyst estimates of $740.35 million. During the same period in the prior year, the company posted $0.68 EPS. The company’s revenue was up 27.0% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. Sell-side analysts forecast that Globus Medical will post 4.74 EPS for the current year.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.